Abstract:Introduction and hypothesis: Bladder pain syndrome (BPS) is poorly understood with both the aetiology and pathophysiology being unknown. Symptoms overlap with other disorders, such as overactive bladder (OAB) and chronic pelvic pain disorders such as endometriosis, making a consensus on how to diagnosis and manage patients challenging. The development of biomarkers for BPS may be the key to understanding more about its pathophysiology, as well as aiding diagnosis, subclassification, and discovering new drug targets for its management. As inflammation is widely understood to hold a central role in BPS, the evaluation of cytokines has gained interest. This article summarises the current literature and understanding of urinary, serum, and bladder tissue cytokines found elevated in patients with bladder pain syndrome. Methods: literature search using Pub Med with the keywords "bladder pain syndrome", "painful bladder syndrome", "bladder pain", "Interstitial cystitis" AND "cytokines" or "inflammation". This study was except from institutional approval. Results: Thirty-six cytokines have been identified as being statistically significantly elevated in either the serum, urine, or bladder tissue of patients with bladder pain syndrome in the 22 studies identified in this review of the literature. These cytokines include those from the interleukin group (n = 14), the CXC chemokine group (n = 5), and the C-C chemokine group (n = 7). Conclusions: CXCL-1, CXCL-8, CXCL-9, CXCL-10, CXCL-11 from the CXC chemokine group, and CCL2, CCL4, CCL5, CCL7, and CCL11 from the C-C chemokine group have been found to be significantly elevated in patients with bladder pain in the literature. Many of these analytes also have supporting evidence for their roles in bladder pain from animal models and studies in other chronic inflammatory conditions. It is likely that a single cytokine will not serve as an adequate biomarker of disease in bladder pain syndrome for either diagnosis or disease severity. Instead, panels of inflammatory mediators may reveal more about the different pathways of inflammation leading to similar presentations of bladder pain in patients.

Caveolin-1 May Participate in the Pathogenesis of Bladder Pain Syndrome/Interstitial Cystitis

Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome

Cytokines in Bladder Pain Syndrome: A Review of the Literature

Potential Urine and Serum Biomarkers in Patients with Bladder Pain Syndrome/Interstitial Cystitis

PACAP/PAC1 Regulation in Cystitis Rats: Induction of Bladder Inflammation Cascade Leading to Bladder Dysfunction

Pelvic floor muscle pain is associated with higher symptom scores and bladder pain perception in women with interstitial cystitis and bladder pain syndrome

Increased expression of TNF ligand-related molecule 1A and death receptor 3 in bladder tissues of patients with painful bladder syndrome/interstitial cystitis.

Molecular pathogenesis of interstitial cystitis/bladder pain syndrome based on gene expression

The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome

Identification of Key Genes in Human Urothelial Cells Corresponding to Interstitial Cystitis/bladder Pain Syndrome in a Lipopolysaccharide-Induced Cystitis Model.

Multimodal Single‐Cell Analyses Outline the Immune Microenvironment and Therapeutic Effectors of Interstitial Cystitis/Bladder Pain Syndrome

Multi‐omics analyses uncover metabolic signatures and gene expression profiles of interstitial cystitis/bladder pain syndrome

Differential expression of histamine receptors in the bladder wall tissues of patients with bladder pain syndrome/interstitial cystitis – significance in the responsiveness to antihistamine treatment and disease symptoms

The role of TSG-6 and uroplakin III in bladder pain syndrome/ interstitial cystitis in rats and humans

Risk Factors for Interstitial Cystitis/painful Bladder Syndrome in Patients with Lower Urinary Tract Symptoms: a Chinese Multi-Center Study

Immunogenic Cell Death Associated Molecular Patterns and the Dual Role of IL17RA in Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis/Bladder Pain Syndrome: a Review and an Update

Latest insights into the pathophysiology of bladder pain syndrome/interstitial cystitis

An Experimental Model of the Epithelial to Mesenchymal Transition and Pro-Fibrogenesis in Urothelial Cells Related to Bladder Pain Syndrome/interstitial Cystitis

A Proteomics Study

MCP-1-induced histamine release from mast cells is associated with development of interstitial cystitis/bladder pain syndrome in rat models.